Navigation Links
Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
Date:8/14/2008

6,538,180 5,513,407

Deferred rent 124,462 124,462

Deferred revenue 1,857,136 1,857,136

--------------------------

Total current liabilities 11,083,924 10,936,045

DEFERRED RENT 111,164 204,256

NON CURRENT PORTION OF CAPITAL LEASE OBLIGATION - 41,641

DEFERRED REVENUE 4,333,257 5,726,131

LONG-TERM DEBT, net 17,899,100 -

--------------------------

Total liabilities 33,427,445 16,908,073

--------------------------

COMMITMENTS

STOCKHOLDERS' EQUITY

Common Stock, $0.001 par value, 100,000,000

shares authorized, 21,751,503 and 21,232,991

shares issued and outstanding at June 30, 2008

(unaudited) and September 30, 2007,

respectively 21,752 21,233

Warrants to purchase 116,183 shares of common stock

for $12.05 per share, with 66,390 exercisable

starting September 30, 2007, and 49,793 shares

exercisable starting March 28, 2008 (unaudited) 1,140,114 526,720

Additional paid-in capital 120,124,752 115,518,201

Accumulated other comprehensive (loss) income (12,664) 4,405

Accumulated deficit (96,471,638) (57,134,233)

--------------------------

Total stockholders' equity 24,802,316 58,936,326

--------------------------

TOTAL
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
2. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
3. Pharmasset Receives Notice of Allowance
4. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
5. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
6. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
9. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
10. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
11. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2008)... Results reveal most respondents against expandin... , , LITTLE FALLS, N.J., Nov. 25 /PRNewswi...statin may lower the cardiovascular risk of health...iversal statin use in older adults, according to a...ome 1,212 participants took part in the online pol...
(Date:11/25/2008)... SOUTH SAN FRANCISCO, Calif., Nov. 25 /PRNewswire...daq: PARD ), a biopharmaceutical company focused...y that it will be exploring,strategic alternative...o allow,the Company to focus its resources on the...duct candidate, and to support the initial commerc...
(Date:11/25/2008)... 200 Patients Enrolled in Clinical Trial to Asses...ard of Care Therapies for Unresectable Hepatocellu... Light Sciences Oncology, Inc. (LSO...a global Phase 3 clinical trial of Light Infusion ...able hepatocellular carcinoma (HCC), also known as...
(Date:11/24/2008)... DEERFIELD, Ill., and OSAKA, Japan, Nov. 24 /PRNe...nd its wholly-owned subsidiary, Takeda Global Rese...ed today that the Arthritis Advisory Committee of ...ended that the FDA approve febuxostat for the tre... vote was 12 to zero in favor of approval, with on...
Breaking Medicine Technology:Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 2Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 2Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 3In promiscuous antelopes the battle of the sexes gets flipped 1380 1In promiscuous antelopes the battle of the sexes gets flipped 1380 2Amarin Commences First Clinical Trial in Cardiovascular ProgramAmarin Commences First Clinical Trial in Cardiovascular Program 7206 1Amarin Commences First Clinical Trial in Cardiovascular ProgramAmarin Commences First Clinical Trial in Cardiovascular Program 7206 2Amarin Commences First Clinical Trial in Cardiovascular ProgramAmarin Commences First Clinical Trial in Cardiovascular Program 7206 3Amarin Commences First Clinical Trial in Cardiovascular ProgramAmarin Commences First Clinical Trial in Cardiovascular Program 7206 4Amarin Commences First Clinical Trial in Cardiovascular ProgramAmarin Commences First Clinical Trial in Cardiovascular Program 7206 5Diabetes Response Service Launches in U S and Canada 7201 1Diabetes Response Service Launches in U S and Canada 7201 2Experts Available to Discuss World AIDS Day HIV AIDS Issues Facing America 7196 1Experts Available to Discuss World AIDS Day HIV AIDS Issues Facing America 7196 2
...2007 - In a late-breaker,presentation at the 42nd ... Study of the Liver (EASL), researchers today pres...PROVE 1 clinical trial,which is the first trial t...gational hepatitis C protease inhibitor telaprevir...feron (peg-IFN) and,ribavirin (RBV) in treatment-n...
...- ZIOPHARM Oncology,Inc. (NASDAQ: ZIOP) presented... at the American Association of Cancer Research,(A...e that,indibulin has distinct biologic and molecul...d strongly suggest a very different,toxicity profi...thy. While indibulin binds to tubulin in general, ...
Other Medicine Technology:Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 2Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 3Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 4Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 5Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 6Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 7Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 8ZIOPHARM Presents Unique Mechanism Data for Indibulin at AACR 2ZIOPHARM Presents Unique Mechanism Data for Indibulin at AACR 3
(Date:12/1/2008)...SHINGTON, Dec. 1 Democr... issued the following statement commemorating Worl...go: http://www.newscom.com/cgi-bin/prnh/20080519/... first World AIDS Day, and while we have made stri...pidemic with both a national and global strategy. ...
(Date:12/1/2008)...W ROCHELLE, N.Y., Dec. 1 Due to th...tion in the field of AIDS/HIV research and clinica...ll provide complimentary access to all archival on... the end of December in honor of World AIDS Day. F...Care and STDs ( www.liebertpub.com/apc ) and A...
(Date:12/1/2008)...IRFAX, Va., Dec. 1 The ...y named Julia E. Bradsher, Ph.D., as its new CEO, ...ing. , , Dr. Bradsher brings to FAAN extens...y fatal allergic reaction. For the past six years,...eting team and strategic planning for all Dey Phar...
(Date:12/1/2008)...robic workouts may prevent cognitive decline in so...hDay News) -- Older adults who exercise regularly...ssels in the brain, a new study shows. , The Un...o be presented Monday at the Radiological Society ..., may help explain other studies that exercise pre...
Breaking Medicine News(10 mins):Health News:Mary Ann Liebert, Inc. Provides Free Online Journal Access in Recognition of World AIDS Day 2Health News:FAAN Names New CEO 2
...leader in genome-derived vaccines, announced today...ne // candidate (TuliVaxTM) that confers protectiv...considered to be one of the most dangerous potenti...ect was funded by a BioDefense Small Business Inno...
...at Karolinska Institutet have discovered a heretof...ther its blood vessels.// New blood vessels are f...ing vessel. These shoots lengthen, branch off and ...municating networks of channels. The process is ca...
... analysis on chromium picolinate published in the ...ics, confirmed that chromium picolinate is //effec... lipid levels in people with type 2 diabetes. The...hromium picolinate, supports the consistent benefi...
...ing initiative by Sir Richard Branson has received...s was welcomed by the doctors and scientific commu...cial as it sounds. The human blood extracted from...ord blood. This can be collected before the placen...
Other Medicine News:Health News:Rhode Island Biotechnology Company Develops Tularemia Vaccine 2Health News:How Bloods Vessels are Linked Together? 2Health News:Chromium Picolinate Effective for Diabetes Care 2Health News:Chromium Picolinate Effective for Diabetes Care 3
...e HI VISION 8500 diagnostic ultrasound scanner com... operation for exceptional imaging and functionali...anced techniques for image enhancement and control...nding, wideband pulse-inversion, tissue harmonics,...
... a 2.4mm channel within a 12.1mm insertion tube. ...ultrasound image for improved reliability, an elec... and a 7.5 and 5.0mhz transducer for deeper ultras...or anatomical orientation and vascular evaluation ...
...CTRA 1400C are designed to achieve low daily opera...This system includes automated primary tube sampli...says in a single setup. It also has an integrated ...nce curves and patient sample dilutions to ensure ...
The ACL 7000 coagulation analyzer is the right choice for any laboratory that needs a full range of testing capabilities in a cost-effective system. You'll have access to a broad test menu including
Medicine Products: